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Background: Atrial ﬁbrillation (AF) is associated with inﬂammation. Cystatin C is not only an inﬂam-
matory marker but also an independent predictor of cardiovascular events. We sought to investigate the
relationship between serum levels of cystatin C and AF in the elderly.
Methods: This study retrospectively investigated 211 paroxysmal and persistent AF patients, 225 per-
manent AF patients (age  60 years), and 204 healthy elderly people in the control group for cystatin C,
high-sensitivity C reactive protein (hsCRP), white blood cell count, biochemical indicators, and
echocardiography.
Results: Compared with the control group, AF groups had higher values for body mass index, systolic
blood pressure, fasting blood glucose, estimated glomerular ﬁltration rate, hsCRP, cystatin C, left atrial
diameter, and left ventricular diameter but lower values of left ventricular ejection fraction (p < 0.05).
After adjustment, correlation analysis showed that the serum level for cystatin C was closely related to
blood urea nitrogen, creatinine, and left atrial diameter, the correlation coefﬁcients were, respectively,
0.490 mg/L, 0.547 mg/L, and 0.521 mg/L (all p < 0.05), but negatively associated with estimated
glomerular ﬁltration rate (r ¼ 0.702, p < 0.001) in AF groups. Multivariable regression analysis showed
the hsCRP, cystatin C, left atrial diameter, and left ventricular ejection fraction entered ﬁnally into the
regression equation (cystatin C, odds ratio: 1.93, 95% conﬁdence interval 1.12e3.07, p ¼ 0.010).
Conclusion: The serum levels of cystatin C showed a signiﬁcant correlation with AF, which indicates that
increased cystatin C is related to the incidence of AF in older patients.
Copyright © 2015, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Atrial ﬁbrillation (AF) is the most common cardiac arrhythmia
and increases in prevalence with aging1e3. While AF prevalence is
<1% among individuals aged <60 years, the prevalence of AF in-
creases to> 7% among those aged 80 years and older1e3. Recently, it
has been estimated that over 10% of the population will develop AF
by the age of 75 years1e3. AF has become one of the leading causes
for hospitalization of the elder patients because it may inducere that they have no conﬂicts
rdiology, The Second Hospital
d, Jinan, Shandong 250033,
tric Emergency & Critical Care Mestroke, heart failure and increase case fatality1,2,4. Unfortunately, its
fundamental pathological mechanisms are not fully clear. Recent
evidence is accumulating to indicate that AF may be closely inter-
related with inﬂammation and inﬂammatory biomarkers2,4e6.
Some studies have conﬁrmed that diverse inﬂammatory factors
participate in pathogenesis and development of AF6e8.
Cysteine protease inhibitor-C (cystatin C) is a member of the
protease inhibitor superfamily. Cystatin C is not only a relatively
more sensitive indicator for evaluating renal function than creati-
nine, but also an independent and strong predictor of cardiovas-
cular events7,9. Recent studies have found that cystatin C is closely
related to the inﬂammatory process or other inﬂammation factors7.
However, it remains unknown whether or not there is correlation
between cystatin C and AF. In this study, the correlation between
cystatin C and AF in the elderly was investigated and its possible
pathogenesis was preliminarily discussed and elucidated.dicine. Published by Elsevier Taiwan LLC. All rights reserved.
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2.1. Patients
A total of 640 consecutively hospitalized patients (age  60
years) were retrospectively investigated between June 2010 and
December 2013 from the Second Hospital of Shandong University.
They included 211 cases of paroxysmal and persistent AF (desig-
nated AF1), 106 men and 105 women with mean age 67.97 ± 7.04
years. There were 225 cases of permanent AF (AF2), 108 men and
117 women, average age 68.90 ± 7.83 years. All cases of AF di-
agnoses were veriﬁed by medical history, physical examination,
electrocardiogram, or dynamic electrocardiogram. The control
group had 204 adults selected after health examination from out-
patients in the Second Hospital of Shandong University, without
diseases or with minor illnesses from cardiac or other departments
following the same exclusion criteria. Of these, 103 were men and
101 women with a mean age of 68.82 ± 8.56 years. Electrocardio-
gram showed sinus rhythm in the control group. There were no
statistically signiﬁcant differences (p > 0.05) in age, sex, or etio-
logical composition among the three groups.
AF was deﬁned and classiﬁed according to the management of
AF of the European Society of Cardiology10. Paroxysmal AF is self-
terminating usually within 48 hours, but may continue for up to 7
days. Persistent AF is present when an AF episode either lasts
longer than 7 days or requires termination by cardioversion, either
with drugs or by direct current cardioversion. Permanent AF is
deﬁned a kind of AF either uncorrectable or not intended to be
corrected by the patient (and physician). Patients with any of the
following conditions were excluded from the study: infectious
diseases; malignant tumors; hyperthyroidism; hypokalemia, hy-
pomagnesemia, hypocalcemia, and acidosis; pneumonia and pul-
monary embolism; moderate and severe anemia; intracranial
hemorrhage; abnormal hepatic (alanine aminotransferase  40 U/
L or aspartate aminotransferase  40 U/L) and renal function
[creatinine  133 mM or glomerular ﬁltration rate (GFR)  70 mL/
min]; respiratory and cerebral dysfunction; immune system and
endocrine metabolic diseases; pregnant women and breastfeeding
women; only with lone AF or with any valvular heart disease; on
some medicines such as statins and angiotensin-converting
enzyme-inhibitors and/or angiotensin II receptor blockers. This
study was conducted in accordance with the ethical principles
stated in the Declaration of Helsinki. The study protocol and
written informed consent were approved by the Ethics Committee
of Clinical Research, the Secondary Hospital of Shandong
University.
2.2. Methods
Peripheral venous blood was obtained from all participants
early in the day after a 12-hour fast. Cystatin C and hsCRP were
measured by means of particle-enhanced turbidimetric immuno-
assays. Its normal reference value is 0e3 mg/L. Other biochemical
indexes were measured in all participants, by using an automatic
biochemical analyzer (Hitachi 7600, Tokyo, Japan) with an enzy-
matic method. The modiﬁed MDRD (Modiﬁcation of Diet in Renal
Disease) Study Formula was applied to estimated GFR (eGFR): eGFR
(mL/min/1.73 m2) ¼ 175  Plasma creatinine1.234 
age0.179  0.79 (if female)11. Blood routine examinationwas tested
in a Sysmex XE-2100 hematology analyzer (Sysmex corporation,
Kobe, Japan). Every participant underwent echocardiography with
a 12-lead MAC1200 electrocardiogram system (GE Healthcare,
Milwaukee, WI, USA). Left atrium diameter, left ventricular diam-
eter, and left vetricular ejection fraction were recorded using a
Philips iE33 (Philips Medical Systems, Bothell, WA, USA).2.3. Statistical analysis
Continuous variables were expressed as mean ± standard de-
viation and categorical variables as percentages. Continuous vari-
ables were compared using one-way ANOVA, and categorical
variables were compared with Chi-square test. The relationship
between variables was evaluated by signiﬁcance calculation of
partial correlation analysis after adjusting classical risk factors
(such as age, sex, and body weight). The overall inﬂuence of
selected risk factors on AF was assessed using binary logistic
regression. Predictors of AF were determined by the multinomial
regression analysis. The association between variables and the
occurrence of AF was represented by odds ratio (OR) and their
accompanying 95% conﬁdence interval (95% CI). SPSS 17.0 (SPSS
Inc., Chicago, IL, USA) was used for all calculations. A p value < 0.05
was considered signiﬁcant.
3. Results
3.1. Comparison of baseline data between AF groups and control
group
Baseline characteristics are shown in Table 1. Comparedwith the
control group, the AF group did not have statistical signiﬁcance in
age, sex, triglycerides, total cholesterol, or high-density lipoprotein
cholesterol (p > 0.05), but had higher values of body mass index,
systolic blood pressure, fasting blood glucose, serum creatinine,
and eGFR (p < 0.05 or p < 0.01). Values of blood urea nitrogen and
low-density lipoprotein cholesterol were signiﬁcantly higher
whereas those of diastolic blood pressure were signiﬁcantly lower
in the AF2 group than those in the control group. Meanwhile there
were no signiﬁcant differences in the values of triglycerides, total
cholesterol, and high-density lipoprotein cholesterol among the
three groups (p > 0.05). Compared with the AF1 group, the AF2
group had higher body mass index, systolic blood pressure, fasting
blood glucose, blood urea nitrogen, creatinine, eGFR, and low-
density lipoprotein (p < 0.05 or p < 0.01).
3.2. Comparison of inﬂammatory indicators between AF groups and
control group
As shown in Table 2, whitebloodcell counts showed no signiﬁ-
cant difference (p > 0.05), whereas therewere signiﬁcant difference
in the values of cystatin C and hsCRP among these groups (p < 0.05
or p < 0.01). Compared with the control group, the AF groups had
higher values of cystatin C and hsCRP (p < 0.05 or p < 0.01).
Furthermore the AF2 group had higher values of cystatin C and
hsCRP than the AF1 group (p < 0.05 or p < 0.01).
3.3. Comparison of echocardiogram parameters between AF groups
and control group
As outlined in Table 3, echocardiogram showed the AF1 group
and the AF2 group had higher values of left atrial diameter and left
ventricular diameter but lower values of left ventricular ejection
fraction than those of the control group (p < 0.05 or p < 0.01).
Compared with the AF1 group, the AF2 group had higher values of
left atrial diameter and left ventricular diameter but lower values of
left ventricular ejection fraction (p < 0.05 or p < 0.01).
3.4. Analysis for correlation between cystatin C, kidney function, or
left atrial diameter
Multivariate linear regression was performed to elucidate
intervariable dependency for the relationship between cystatin C,
Table 1
Comparison of baseline data between atrial ﬁbrillation (AF) and control groups.
Variables Control group AF1 group (paroxysmal and persistent) AF2 group (permanent)
Number of cases 204 211 225
Age (y), mean ± SD 68.82 ± 8.56 67.97 ± 7.04 68.90 ± 7.83
Male, n, (%) 103 (50.49) 106 (50.23) 108 (48.00)
Body mass index (kg/m2) 26.31 ± 4.38 28.89 ± 5.93** 29.04 ± 6.12**#
Systolic blood pressure (mmHg) 131.34 ± 11.26 144.90 ± 14.85** 146.87 ± 15.70**#
Diastolic blood pressure (mmHg) 82.90 ± 10.46 79.64 ± 11.08* 78.83 ± 11.02*
Fasting blood glucose (mM) 5.87 ± 1.25 6.26 ± 2.21* 6.37 ± 2.45**#
Blood urea nitrogen (mM) 5.95 ± 2.28 6.31 ± 3.19 6.59 ± 3.15**
Creatinine (mM) 60.78 ± 12.54 87.61 ± 25.82* 88.70 ± 26.48**
Estimated glomerular ﬁltration rate (mL/min/1.73 m2) 107.83 ± 21.60 99.86 ± 19.15* 94.51 ± 15.98**#
Triglycerides (mM) 1.18 ± 0.55 1.21 ± 0.47 1.24 ± 0.58
Total cholesterol (mM) 4.45 ± 0.87 4.37 ± 0.79 4.50 ± 0.72
High-density lipoprotein (mM) 1.32 ± 0.35 1.26 ± 0.26 1.21 ± 0.30
Low-density lipoprotein (mM) 2.59 ± 0.65 2.68 ± 0.57 2.73 ± 0.67*
Compared with control group: *p < 0.05, **p < 0.01; compared with AF1 group: #p < 0.05, p < 0.01.
Table 2
Comparison of inﬂammatory indicators between atrial ﬁbrillation and control
groups.
Variables Control group AF1 group AF2 group
White blood cell count ( 109/L) 5.88 ± 1.84 6.09 ± 1.90 6.13 ± 2.02
hsCRP (mg/l) 1.31 ± 1.05 2.75 ± 1.18** 3.91 ± 1.26**##
Cystatin C (mg/l) 0.84 ± 0.17 1.07 ± 0.25* 1.38 ± 0.40**#
Compared with control group, *p < 0.05, **p < 0.01; compared with AF1 group,
#p < 0.05, ##p < 0.01.
AF ¼ atrial ﬁbrillation; hsCRP ¼ high-sensitivity C reactive protein.
Table 3
Comparison of ultrasound parameters of left heart between atrial ﬁbrillation and
control groups.
Variables Control group AF1 group AF2 group
Left atrial diameter (mm) 33.69 ± 3.35 43.56 ± 10.68** 47.13 ± 11.75**#
Left ventricular
diameter (mm)
49.50 ± 7.37 52.64 ± 11.34* 54.25 ± 11.42**#
Left ventricular ejection
fraction (%)
54.83 ± 8.52 50.18 ± 10.56* 47.36 ± 12.25**#
Compared with control group, *p < 0.05, **p < 0.01; compared with AF1 group,
#p < 0.05, p < 0.01.
AF ¼ atrial ﬁbrillation.
Table 4
Analysis for correlation between cystatin C, kidney function, and left atrial diameter.
Variables r p
Blood urea nitrogen 0.490 0.029
Serum creatinine 0.547 0.007
Estimated glomerular ﬁltration rate 0.702 <0.01
Left atrial diameter 0.521 <0.01
Table 5
Multiple logistic regression analysis of predictive factors for atrial ﬁbrillation.
Variables b SE OR p 95%CI
High-sensitivity C reactive protein 0.85 0.91 2.05 0.008 1.82e3.64
Cystatin C 0.60 0.85 1.93 0.010 1.12e3.07
Left atrial diameter 0.57 0.48 1.86 0.031 1.16e2.85
Left ventricular ejection fraction 0.41 0.73 1.46 0.047 0.95e2.71
CI ¼ conﬁdence interval; OR ¼ odds ratio; SE ¼ standard error.
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after adjusting for age, sex, body weight, blood pressure, fasting
blood glucose, and serum lipid, cystatin C was closely related to
blood urea nitrogen, serum creatinine, and left atrial diameter, and
their correlation coefﬁcients were 0.490, 0.547, and 0.521, respec-
tively (all p < 0.05), whereas cystatin C was inversely related to
eGFR (r ¼ 0.702, p < 0.001).3.5. Multinomial analysis of AF risk factors
As presented in Table 5, all selected variables from AF groups
and the control group were analyzed by stepwise regression anal-
ysis and the related indicators were picked out. Finally, hsCRP,cystatin C, left atrial diameter, systolic blood pressure, and left
ventricular ejection fraction were entered into the regression
equation (Table 5; hsCRP: OR 2.05, 95% CI 1.82e3.64, p ¼ 0.008;
cystatin C: OR 1.93, 95% CI 1.12e3.07, p¼ 0.010; left atrial diameter:
OR 1.84, 95% CI 1.16e2.85, p ¼ 0.031; and left ventricular ejection
fraction: OR 1.46, 95% CI 0.95e2.71, p ¼ 0.047).
4. Discussion
In recent years, a large number of studies have conﬁrmed that
cystatin C is likely to be an independent risk factor of cardiovascular
disease7,12. The close relationship between cystatin C and cardio-
vascular disease is not only attributed to kidney function but is also
thought to be mediated by inﬂammatory mechanisms7,13,14. The
unique association of AF with renal dysfunction could be explained
by the fact that AF and renal dysfunction share a number of risk
factors15. Although mechanical stress on the atrium due to volume
overload could be the mediating factor that leads to the develop-
ment of AF in patients with renal dysfunction, this does not explain
the development of AF in earlier phases of renal dysfunction. Due to
there being not a unanimous opinion about the relationship be-
tween AF, renal function, and cystatin C, some studies make the
beneﬁcial attempt to these aspects13,14. Both the ARIC Study13 and
the Heart and Soul Study14 demonstrate only the association be-
tween AF and renal function estimated by urinary albumin-to-
creatinine ratio and cystatin C-based glomerular ﬁltration rate
rather than cystatin C itself. The Malm€o Diet and Cancer study9
provide evidence that only natriuretic peptides and CRP instead
of cystatin C improve prediction of incident heart failure and AF in
the general population in addition to conventional risk factors.
However, these studies9,13,14 do not discuss the relationship be-
tween cystatin C and AF, particularly in the elderly.
One possible mechanism for a higher prevalence of AF in early
stages of renal insufﬁciency could be explained by inﬂammation15.
Furthermore, many researchers have ascertained that cystatin C has
a linear positive correlation with a variety of inﬂammatory cyto-
kines such as hsCRP and reﬂects the severity of inﬂammatory
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ments may also affect the phagocytic and chemotactic functions of
granulocytes and participate in the inﬂammatory process9,12. It is
worth mentioning that Targonski et al16 found that the serum
concentration of hsCRP is closely, positively correlated with the
diameter size of left atrium. This ﬁnding suggests that inﬂamma-
tory cytokines may be involved in the atrial remodeling process.
The current study also showed that the serum concentration of
cystatin C coincided with left atrial diameter (r ¼ 0.521; p < 0.001).
It is reported that, in atrial tissue of patients with AF, inﬂam-
mation results in inﬂammatory cell inﬁltration, oxidative stress and
damage, followed by repair of the local tissue damage by ﬁbrous
tissue. As a result of this pathological process, atrial remodeling
ensues6e8. Therefore, the inﬂammatory cytokines such as cystatin C
and hsCRP may modulate the inﬂammatory process, participate in
the hypertrophic degeneration of atrial muscle ﬁber, induce atrial
structural abnormalities in patients with AF, and thus lead to atrial
electrical remodeling6e8. Inﬂammation is closely associated to AF
and may be the important mediumwhich links AF with known risk
factors (such as high blood pressure and obesity) responsible for
the development of AF1,3,6,17. Even the atrial pathoanatomy in lone
AF showed inﬂammatory inﬁltration, muscle cell necrosis and
ﬁbrosis1,17. Modern studies have conﬁrmed that chronic inﬂam-
mation has an arrhythmogenic effect giving rise to the develop-
ment of AF in susceptible populations. Inﬂammatory markers could
be the result of AF rather than the cause of AF18.
The different types of AFs may have different structural, patho-
logical, and electrophysiological bases19e21. Furthermore,Wu et al22
reported that the effects of inﬂammation in different type of AF
were distinct. For instance, Wu et al23 held that CRP was signiﬁ-
cantly associated with persistent and permanent AF risk, but not
with paroxysmal AF. Coincidentally, Chung et al24 and Watanabe
et al25 reported that longer duration of AF has been found to be
associated with higher hsCRP levels compared with shorter dura-
tion of AF. Similar to previous studies, in this study, monofactorial
analysis showed that the serum levels of hsCRP and cystatin C in the
AF2 group were higher than those in the AF1 and control groups.
Multifactor analysis showed that both cystatin C and hsCRP, entered
in the regression equation, had higher OR values (3.23 and 3.74,
respectively). However, this study showed no signiﬁcant relation-
ship between white blood cell count and risk of incident AF, which
differs from the result of the Framingham Heart Study26.
The risk of patients with metabolic syndrome developing AF is
increased by 88%, when compared with those without metabolic
syndrome3. AF and metabolic syndrome share common risk fac-
tors: obesity, hypertension, hyperglycemia, and hyperlipidemia.
The patients with higher level of cystatin C have a higher metabolic
state: higher body mass index, blood pressure, blood sugar and
lipid levels12. Studies have shown that cystatin C is closely related
to metabolic syndrome3,7. Insulin resistance is not only the patho-
genesis of metabolic syndrome but also may be the pathological
process that connects cystatin C with metabolic syndrome7,27.
Presumably, from another perspective, AF and metabolic syndrome
may have a common pathological relationship mediated by in-
ﬂammatory biomakers such as cystatin C. Similar to previous
studies, the current study conﬁrmed that body mass index, systolic
blood pressure, fasting blood glucose, and low-density lipoprotein
cholesterol in AF groups, especially in the permanent AF group
(AF2), were higher than those in the control group (Table 1). Blood
pressure is the most common risk factor of AF; moreover, systolic
blood pressure is a better predictor of AF than diastolic blood
pressure3. It is particularly signiﬁcant for aged patients with AF as
in the elderly, hypertension is characterized by elevated systolic
blood pressure. However, the multivariable analysis has not
revealed that systolic blood pressure independently correlated toAF in this study. Linssen et al28 pointed out that AF facilitates the
progression of heart failure in several ways. Due to rapid heart
rates, an irregular ventricular rhythm, loss of atrioventricular syn-
chrony, and an increase in mitral and tricuspid regurgitation, AF
may further decrease cardiac output and aggravate heart failure28.
As shown in this study, left ventricular ejection fraction was also
independently aligned with AF. Some studies have validated
obesity as an independent risk factor for predicting AF3. However;
this study showed that body mass index did not enter the regres-
sion equation in the multivariate analysis.
4.1. Study limitations
There were several limitations in this study. First, this is a
retrospective study which was carried out at a single center. Re-
searchers were not blinded to the clinical and laboratory informa-
tion including variables of cystatin C and AF. Second, the sample
size, although small, was sufﬁcient to display differences between
the control and the AF groups; however, further studies with a
larger scale of cohorts are needed to conﬁrm these results. Addi-
tionally, some inﬂammatory indicators such as interleukin-6 and
tumor necrosis factor-a were not applied in this study. Although
these indicators probably do not affect the conclusion of this study,
they may have made an impact on the estimate for action degree of
hsCRP and cystatin C in this study. Furthermore, the relationship
between cystatin C and AF was not veriﬁed by pathological and
molecular biological methods. Finally, we did not further divide the
group with nonpermanent AF into groups with paroxysmal and
persistent AF according to AF duration.
5. Conclusion
In summary, as a new inﬂammatory factor, cystatin C is inti-
mately associated with AF and may be an important predictor for
the occurrence and development of AF in the elderly. However, the
speciﬁc relationship and precise mechanism between cystatin C
and AF will need to be veriﬁed by further basic and clinical studies.
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